Dear Colleagues, Dear Friends, It is with great honour that we invite you to the 17th International Conference of Contemporary Oncology, a gathering that stands at the forefront of cancer research and clinical innovation. This conference arrives at a pivotal moment when oncology is rapidly evolving through breakthroughs in precision medicine, immunotherapy, and technological integration. The collective efforts of researchers, clinicians, and innovators worldwide are transforming cancer care from a one-size-fits-all approach to one that is deeply personalized and biologically driven. We are witnessing breakthroughs in our understanding of the molecular and genetic basis of cancer development, which is driving the development of next-generation immunotherapy treatments. Over recent years, we have witnessed remarkable progress in understanding the molecular and genetic underpinnings of cancer, which has enabled the development of highly targeted therapies and next-generation immunotherapies. Emerging modalities such as bispecific antibodies, CAR T-cell therapies targeting solid tumours, and personalised cancer vaccines are reshaping treatment paradigms, offering new hope and improved outcomes for patients across diverse cancer types. Additionally, artificial intelligence and advanced diagnostic tools are not only enhancing early detection but also optimising treatment decisions to maximise efficacy while minimising side effects. This year conference will have a special session focused on the genealogy and future of cell therapies. In parallel, the European Union is advancing a robust regulatory and policy framework designed to accelerate innovation and patient access in oncology. The European Health Data Space (EHDS), Joint Clinical Assessments (JCA) under the Health Technology Assessment (HTA) Regulation, and strategies like the EU Life Sciences Strategy, upcoming Biotech Act, and Europe's Beating Cancer Plan form a cohesive ecosystem accelerating oncology research and therapy development by enhancing data access, standardizing evaluations, and prioritizing cancer innovations e.g. biopharmaceutical innovation, digital health integration, and sustainable healthcare ecosystems across member states. What is more, the broad spectrum of supporting instruments should enable further scientific and therapeutic developments. These trends are also visible in the identification of leading areas of specialisation and the building of competitiveness of countries and regions, for example through specific so-called smart specialisations relating to the prevention, diagnosis and treatment of lifestyle diseases such as cancer, and the accompanying development of medical biotechnology. Looking forward, the 17th International Conference of Contemporary Ocology will highlight innovative frontiers including novel drug platforms, combination therapies, and the integration of digital health technologies that will further elevate the standard of care. Amidst these scientific advancements, a patient-centered approach remains paramount, recognizing the individual's role as a partner in their treatment journey. We invite all participants to engage deeply with the cutting-edge research and discussions that will unfold during this event, fostering collaborations that will accelerate the translation of discoveries into lifesaving therapies. Together, we can envision and realize a future where cancer is increasingly preventable, manageable, and ultimately curable.